<DOC>
	<DOC>NCT00139906</DOC>
	<brief_summary>This study is to assess the safety and tolerability of a five-day titration schedule (using twice daily dosing for the first three days) to achieve the highest proposed dose of 40 mg daily. The study duration is two months.</brief_summary>
	<brief_title>Twice Daily Titration Study of Bifeprunox in Subjects With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<criteria>Subjects who have current diagnosis of Schizophrenia or Schizoaffective disorder Body weight of 100250 lbs Male or females 1855 years of age Subjects who are acutely psychotic Subjects with current Axis I primary psychiatric diagnosis other than schizophrenia, at significant risk of suicide</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2006</verification_date>
	<keyword>Titration Study</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>BID dosing</keyword>
	<keyword>Pharmacokinetic</keyword>
</DOC>